|
|
|
|
| |
|
|
Soares,P.B.; Jeremias,T.S.; Alvarez-Silva,M.; Licínio,M.A.; Santos-Silva,M.C.; Vituri,C.L.. |
Imatinib mesylate (IM) is used to treat chronic myeloid leukemia (CML) because it selectively inhibits tyrosine kinase, which is a hallmark of CML oncogenesis. Recent studies have shown that IM inhibits the growth of several non-malignant hematopoietic and fibroblast cells from bone marrow (BM). The aim of the present study was to evaluate the effects of IM on stromal and hematopoietic progenitor cells, specifically in the colony-forming units of granulocyte/macrophage (CFU-GM), using BM cultures from 108 1.5- to 2-month-old healthy Swiss mice. The results showed that low concentrations of IM (1.25 µM) reduced the growth of CFU-GM in clonogenic assays. In culture assays with stromal cells, fibroblast proliferation and α-SMA expression by... |
Tipo: Info:eu-repo/semantics/article |
Palavras-chave: Bone marrow stromal cell; Hematopoietic progenitors; Imatinib mesylate; Myelosuppression. |
Ano: 2013 |
URL: http://www.scielo.br/scielo.php?script=sci_arttext&pid=S0100-879X2013000100039 |
| |
|
|
Oliveira,G.A.P.; Costa,E.S.; Freitas,M.S.; Dutra,F.F.; Maia,S.F.; Guerra,M.C.; Tabernero,M.D.; Borojevic,R.; Otazu,I.B.; Silva,J.L.. |
Chronic myeloid leukemia (CML) is rare in the pediatric population, accounting for 2-3% of childhood leukemia cases, with an annual incidence of one case per million children. The low toxicity profile of imatinib mesylate has led to its approval as a front-line therapy in children for whom interferon treatment has failed or who have relapsed after allogeneic transplantation. We describe the positive responses of 2 children (case 1 - from a 7-year-old male since May 2005; case 2 - from a 5-year-old female since June 2006) with Philadelphia-positive chromosome CML treated with imatinib (300 mg/day, orally) for up to 28 months, as evaluated by morphological, cytogenetic, and molecular approaches. Our patients are alive, are in the chronic phase, and are in... |
Tipo: Info:eu-repo/semantics/report |
Palavras-chave: Chronic myeloid leukemia; Imatinib mesylate; Minimal residual disease; Children. |
Ano: 2010 |
URL: http://www.scielo.br/scielo.php?script=sci_arttext&pid=S0100-879X2010000600009 |
| |
|
|
|